Supplementary Tables 1-8 from Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER<sup>+</sup> Breast Cancer

Supplementary Tables 1-8 from Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER<sup>+</sup> Breast Cancer

<p>Suppl. Tables S1-S8</p>

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Gary N. Schwartz (16005870) (author)
مؤلفون آخرون:	Peter A. Kaufman (16005873) (author), Karthik V. Giridhar (16005876) (author), Jonathan D. Marotti (16005879) (author), Mary D. Chamberlin (15036341) (author), Bradley A. Arrick (16005882) (author), Grace Makari-Judson (16005885) (author), Matthew P. Goetz (8863130) (author), Shannon M. Soucy (16005888) (author), Fred Kolling (16005891) (author), Eugene Demidenko (16005894) (author), Todd W. Miller (16005897) (author)
منشور في:	2025
الموضوعات:	Cancer Therapeutic Research and Development Clinical Research and Trials Breast Cancer Clinical Trial Results Translational Research
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة

Figure S1 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
حسب: Séverine Guiu (22618776)
منشور في: (2025)

Figure S2 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
حسب: Séverine Guiu (22618776)
منشور في: (2025)

Figure 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
حسب: Richard D. Baird (15004350)
منشور في: (2025)

Figure 2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
حسب: Richard D. Baird (15004350)
منشور في: (2025)

Figure 3 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
حسب: Richard D. Baird (15004350)
منشور في: (2025)

Table 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
حسب: Richard D. Baird (15004350)
منشور في: (2025)

Table 2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
حسب: Richard D. Baird (15004350)
منشور في: (2025)

Figure 1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
حسب: Timothy A. Yap (15028749)
منشور في: (2025)

Figure 2 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
حسب: Timothy A. Yap (15028749)
منشور في: (2025)

Table 1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
حسب: Timothy A. Yap (15028749)
منشور في: (2025)

Table 2 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
حسب: Timothy A. Yap (15028749)
منشور في: (2025)

Table 3 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
حسب: Timothy A. Yap (15028749)
منشور في: (2025)

Table 4 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
حسب: Timothy A. Yap (15028749)
منشور في: (2025)

Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
حسب: Tom Wei-Wu Chen (15053003)
منشور في: (2025)

Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
حسب: Tom Wei-Wu Chen (15053003)
منشور في: (2025)

Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
حسب: Tom Wei-Wu Chen (15053003)
منشور في: (2025)

Supplementary Figure 4 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
حسب: Tom Wei-Wu Chen (15053003)
منشور في: (2025)

Supplementary Table 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
حسب: Tom Wei-Wu Chen (15053003)
منشور في: (2025)

Figure 2 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
حسب: Lillian L. Siu (14851075)
منشور في: (2025)

Figure 3 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
حسب: Lillian L. Siu (14851075)
منشور في: (2025)

Table 1 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
حسب: Lillian L. Siu (14851075)
منشور في: (2025)

Supplementary Figure S1 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
حسب: Lillian L. Siu (14851075)
منشور في: (2025)

Supplementary Figure S2 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
حسب: Lillian L. Siu (14851075)
منشور في: (2025)

Supplementary Figure S3 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
حسب: Lillian L. Siu (14851075)
منشور في: (2025)

Supplementary Figure S4 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
حسب: Lillian L. Siu (14851075)
منشور في: (2025)

Supplementary Figure S5 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
حسب: Lillian L. Siu (14851075)
منشور في: (2025)

Supplementary Table S5 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
حسب: Lillian L. Siu (14851075)
منشور في: (2025)

Figure S1 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
حسب: Xiu-Zhi Zhu (22436380)
منشور في: (2025)

Figure S2 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
حسب: Xiu-Zhi Zhu (22436380)
منشور في: (2025)

Figure S3 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
حسب: Xiu-Zhi Zhu (22436380)
منشور في: (2025)

Figure S4 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
حسب: Xiu-Zhi Zhu (22436380)
منشور في: (2025)

Figure S5 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
حسب: Xiu-Zhi Zhu (22436380)
منشور في: (2025)

Figure S6 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
حسب: Xiu-Zhi Zhu (22436380)
منشور في: (2025)

Figure S7 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
حسب: Xiu-Zhi Zhu (22436380)
منشور في: (2025)

Figure S8 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
حسب: Xiu-Zhi Zhu (22436380)
منشور في: (2025)

Table S1 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
حسب: Xiu-Zhi Zhu (22436380)
منشور في: (2025)

Table S2 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
حسب: Xiu-Zhi Zhu (22436380)
منشور في: (2025)

Table S3 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
حسب: Xiu-Zhi Zhu (22436380)
منشور في: (2025)

Table S4 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
حسب: Xiu-Zhi Zhu (22436380)
منشور في: (2025)

Table S5 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
حسب: Xiu-Zhi Zhu (22436380)
منشور في: (2025)